Key facts
- CELEX Oncology’s last known valuation is $3.2M (May 2017).
- It has raised $320K; the latest was Accelerator/Incubator in Sep 2025.
- Notable investors include EIT Health, Grow London, Namier Capital Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for CELEX Oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for CELEX Oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CELEX Oncology
Operator of a biotechnology platform intended to support the development of targeted cancer therapies. The company offers research-driven therapeutics based on long-term studies and biological understanding, enabling patients with complex tumors access to focused treatment approaches.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2016
- Employees
- 9
- Website
- celexoncology.com/
- Ownership
- Privately Held (backing)
CELEX Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CELEX Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CELEX Oncology in its N-PORT filings yet. We sweep new filings monthly.